Sustainable Public Pharmaceutical Expenditures Financing Model : Roadmap and Process Management |
Continued economic uncertainty and rising healthcare expenditures are making it difficult for many countries to achieve the goal of access to health care services for all segments of their populations within an affordable cost structure. To address these issues, many other countries have initiated cost control mechanisms, focused primarily on pharmaceutical expenditures. A new report from Deloitte Turkey looks specifically how these issues are being addressed in Turkey and offers a possible roadmap for the Turkish government, as well as other countries, to develop a secure and sustainable financing model for public pharmaceutical expenditures.
Sustainable Public Pharmaceutical Expenditures Financing Model : Roadmap and Process Management
(1526.31 KB)
Material on this website is © 2013 Deloitte Global Services Limited, or a member firm of Deloitte Touche Tohmatsu Limited, or one of their affiliates. See